Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Bladder Cancer treatment details. Biologic therapy. Memorial Sloan-Kettering Cancer Center, New York, NY, United States

Survival: 7.1 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: New York, NY
Hospital: Memorial Sloan-Kettering Cancer Center
Journal: Link
Date: 2/2010

This phase II trial involved 45 previously-treated metastatic urothelial cancer patients with a median age of 64 years; 71% were male.

Patients were treated with the biologic therapy agent sunitinib, which is an inhibitor of proteins involved in supporting tumor blood supply.

There was one reported treatment-related death due to heart attack. Grade 4 nausea, fatigue, lymphopenia, and thrombocytopenia were also reported.

The median overall survival was 7.1 months.

This study was partially supported by Pfizer Inc., the makers of sunitinib (Brand name: Sutent).

Correspondence: Dr. Dean Bajorin; email:

E-mail to a Friend Email Physician More Information